The Potential of a Low Glutamate Diet as a Treatment for Pediatric Epilepsy

Sponsor
American University (Other)
Overall Status
Completed
CT.gov ID
NCT04545346
Collaborator
Children's National Research Institute (Other)
45
1
2
20
2.3

Study Details

Study Description

Brief Summary

The study is investigating if following the low glutamate diet for 1 month, as compared to care as usual, can improve seizure frequency, severity, and duration; cognitive functioning; and/or quality of life in children with epilepsy.

Condition or Disease Intervention/Treatment Phase
  • Other: Low Glutamate diet
N/A

Detailed Description

Epilepsy is estimated to effect 470,000 children within the U.S. About a third of epilepsy patients are refractory. For these patients, dietary therapy is an alternative option. However, current dietary therapies present issues with compliance, palatability, adverse events, and providing necessary nutrients for brain growth and development during childhood. A dietary option that can improve tolerability, increase compliance, and reduce or eliminate adverse effects, while also optimizing nutrient intake, is critical for the advancement of dietary therapy options in epilepsy.

Glutamate is found in the diet as a flavor enhancer; and is also an important neurotransmitter in the body which mediates seizure activity. Dietary sources of free glutamate are common and include numerous food additives (including many hidden sources) and some items which naturally contain higher amounts of glutamate. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake, which can protect against the negative effects caused by high glutamate concentrations in the brain. Additionally, the low glutamate diet is balanced, nutritious and palatable, with no side effects.

The study is investigating if following the low glutamate diet for 1 month can improve seizure frequency, severity, and duration; cognitive functioning; and/or quality of life, in children with epilepsy. Participation in the study will be done virtually and over a 2- or 3- month study period, depending on group randomization. All participants will have the opportunity to undergo dietary training and follow the diet.

Study Design

Study Type:
Interventional
Actual Enrollment :
45 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled trialRandomized controlled trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Potential of a Low Glutamate Diet in Refractory Pediatric Epilepsy Patients
Actual Study Start Date :
Oct 15, 2020
Actual Primary Completion Date :
Jun 15, 2022
Actual Study Completion Date :
Jun 15, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Wait-listed control

Participants continue care as usual. All all medications must be kept constant during the study period, unless medically necessary.

Experimental: Low Glutamate diet

Participants are put on the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.

Other: Low Glutamate diet
Participants will be given extensive online dietary training and assigned to follow the low glutamate diet for one month. The low glutamate diet reduces the consumption of free glutamate, while optimizing dietary micronutrient and antioxidant intake.

Outcome Measures

Primary Outcome Measures

  1. Change in seizure frequency [At 1 month post treatment]

    All families will keep a seizure diary recording the number of daily seizures. This will be used to accurately determine these variables for the last week, which will be recorded on seizure assessment forms.

  2. Change in seizure severity [At 1 month post treatment]

    . During the last week of each study period, families will be asked to complete a seizure assessment form. This will include a subjective rating scale for seizure severity with a minimum score of 0 (not severe) and a maximum score of 10 (very severe).

  3. Change in seizure duration [At 1 month post treatment]

    All families will keep a seizure diary recording the duration of seizures. This will be used to accurately determine these variables for the last week, which will be recorded on seizure assessment forms.

Secondary Outcome Measures

  1. The effect of a 1-month low-glutamate diet on quality of life in children with epilepsy. [At 1 month post treatment]

    Parents will be asked to complete the Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55). This 55-question quality of life questionnaire has been validated for children ages 4 and older and is used to assess the participant's cognitive, emotional, social, and physical functioning.

  2. The effect of a 1-month low-glutamate diet on cognitive functioning in children with epilepsy. [At 1 month post treatment]

    Cognitive function will be assessed via CNSVS, a computerized neurocognitive testing software.

  3. Examine change in resting state brain waves after 1-month on the low glutamate diet [At 1 month post treatment]

    Electroencephalography (EEG) will be offered to all participants. Four minutes of eyes-closed and eyes-open resting state EEG data will be recorded at the end of the baseline, wait-listed control, and active intervention periods in a sound-attenuated, air-conditioned room. Participants will sit in a comfortable chair in front of a computer monitor. For eyes-closed recordings, participants will be instructed to sit as still as possible, while staying relaxed but awake. For eyes-open recordings, participants will be instructed to sit as still as possible and to focus on a fixation point on the screen while keeping blinking to a minimum, if possible. Participants will be monitored to make sure they are complying with condition instructions. Mean power (total power of frequency band/width of frequency band) and relative power (absolute power of frequency band/total power or percent) will be calculated for delta, theta, alpha, beta, gamma, high gamma, and total power.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Years to 21 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 4 or more seizures per month

  • Willing to keep all medications constant during the study.

  • All medications have remained constant for 30 days prior to study enrollment

  • Any previously attempted dietary therapies stopped before study enrollment

Exclusion Criteria:
  • Known or suspected inborn errors of metabolism

  • Non-English speaking households

Contacts and Locations

Locations

Site City State Country Postal Code
1 American University Washington District of Columbia United States 20016

Sponsors and Collaborators

  • American University
  • Children's National Research Institute

Investigators

  • Principal Investigator: Kathleen Holton, MPH, PhD, American University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kathleen Holton, Associate Professor, American University
ClinicalTrials.gov Identifier:
NCT04545346
Other Study ID Numbers:
  • IRB- 2019- 240
First Posted:
Sep 11, 2020
Last Update Posted:
Jul 20, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2022